Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of ascending doses of a
novel oral formulation of Fenretinide to adult cystic fibrosis (CF) patients, once-daily for
21 days (treatment cycle). This study will include up to three (3) dose levels with minimum 7
day breaks in between treatment cycles. For each dose level, blood samples will be collected
for exploratory pharmacokinetic (PK) and pharmacodynamic (PD) evaluation.